Status:
COMPLETED
Prevalence of Antimicrobial-resistant Pathogens in Patients Admitted for UTIs
Lead Sponsor:
Olive View-UCLA Education & Research Institute
Collaborating Sponsors:
Centers for Disease Control and Prevention
IHMA laboratories
Conditions:
Urinary Tract Infections
Urosepsis
Eligibility:
All Genders
18+ years
Brief Summary
Between 2013-2014, our study network of U.S. emergency departments, EMERGEncy ID NET, found that the rate of fluoroquinolone-resistant E. coli was 11.7% among all patients, 6.3% in uncomplicated and 1...
Eligibility Criteria
Inclusion
- Age greater than or equal to 18 years;
- Admitted to the hospital through the ED;
- Primary reason for admission is treatment of UTI with or without sepsis (i.e., ED diagnosis of UTI and/or sepsis); and
- Provide verbal or written consent to participate in the study or if patient is unable to provide consent (e.g., altered mental status), consent obtained from a legal authorized representative.
Exclusion
- patients will be later excluded if :
- they are unable to provide a urine specimen for culture; or
- their urine culture yields no growth or is contaminated (see definition of positive urine culture below). Note: If participant's urine culture is contaminated but their blood culture is positive for a uropathogen, they will not be excluded.
Key Trial Info
Start Date :
February 8 2018
Trial Type :
OBSERVATIONAL
Allocation :
ACTUAL
End Date :
December 31 2020
Estimated Enrollment :
801 Patients enrolled
Trial Details
Trial ID
NCT03346603
Start Date
February 8 2018
End Date
December 31 2020
Last Update
July 8 2021
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Olive View-UCLA Medical Center
Sylmar, California, United States, 93311